ASCO 2020：11项近现代研究入选口头报告，17项Poster报告

受全球新的冠非典受到影响，原定于5月末29日~6月末2日在芝加哥举行的美国临床学会（ASCO）高峰会上周将首次以本站上形式举办，这是目前最大规模的本站上嘉年华会。现在，全体会议的内容可考题公布，共103个sessions，东亚总共11项研究课题入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他松用作HER2+转回性前列腺乳癌（PHOEBE）：一项III期随机检验。

第二场：转回性前列腺乳癌

创作者：东亚医学科学院疗养院徐兵河名誉教授、马飞名誉教授，上海交通大学附设疗养院胡夕春名誉教授等

内容可号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴性前列腺乳癌标准放射治疗后卡培他松可维持节拍化学放射治疗的III期检验（SYSUCC-001）。

第二场：前列腺乳癌—发散/区域/常规放射治疗

创作者：中山大学防治中心王之树森名誉教授等

内容可号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

运用转回性脑的表型特征来预测膀胱中循环DNA扫描的概率: 新的基本功能对抗来由对手

第二场：新的基本功能解决来由问题

创作者：李美芹 李德兰等

内容可号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为后半期脾本站粒体乳癌的一本站放射治疗：一项闭馆ID、随机、多中心II/III期检验。

第二场：小肠乳癌—胃腹腔、胰腺和脾胆

创作者：东南大学华西疗养院毕锋名誉教授、程子华八一疗养院秦叔逵名誉教授等

内容可号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

东亚后半期脾乳癌病症阿帕替尼二本站放射治疗：一项随机、安慰剂对照、双盲III期研究课题

第二场：小肠乳癌—胃腹腔、胰腺和脾胆

创作者：程子华八一疗养院秦叔逵名誉教授、东南大学华西疗养院李秋名誉教授等

内容可号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后半期住院性卵巢乳癌二次本站粒体减灭术的一项随机III期检验：SOC1 / SGOG-OV2。

研讨：小儿乳癌症

创作者：上海交通大学附设中山疗养院臧荣余名誉教授等

内容可：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳癌根治性子宫畸形后常规放射治疗中的序贯放化学放射治疗对比单独阿兹海默或同步放化学放射治疗（STARS研究课题）：一项随机、对照、闭馆ID的III期检验。

全体会议：小儿乳癌症

创作者：中山大学防治中心白云名誉教授、刘继红名誉教授等

内容可号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：常规吉非替尼对比化学放射治疗用作可切除的EGFR突变的N1-N2期NSCLC-随机III期临床检验的之后总体生存分析方法。

研讨：白血病—非小本站粒体发散-区域/小本站粒体/其他胸部

创作者：广东省人民疗养院吴一龙名誉教授等

内容可号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变寡转回非小本站粒体白血病病症一本站酪氨酸激酶胺合组或不合组积极前本站发散阿兹海默：III期闭馆ID临床随机检验（SINDAS）的中期结果（NCT02893332）。

研讨：白血病-非小本站粒体转回

创作者：乐山市人民疗养院曾铭名誉教授等

内容可：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性丧命-1（PD-1）的人源化IgG4基因工程合组阿昔替尼用作转回性黏膜黑色素刺毛病症的Ib期研究课题的总生存期和生物多种类型分析方法。

研讨：黑色素刺毛/皮肤乳癌

创作者：北京大学疗养院郭军、盛锡楠名誉教授等

内容可：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全性和结果：通用CAR-T本站粒体首次人体检验放射治疗住院/难治性T本站粒体急性淋巴本站粒体白血病（r/r T-ALL）的安全性和。全体会议：开发中的放射治疗技术-免疫放射治疗。创作者：王之林欣等内容可：3013广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在后半期腹腔表皮本站粒体乳癌病症中的系统设计：一项随机的闭馆IDII期检验（ORIENT-2）。全体会议：小肠乳癌-胃腹腔乳癌、胰腺乳癌和脾胆道乳癌创作者：徐建明名誉教授等内容可：4511广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T本站粒体对髓母本站粒体刺毛的根除性放射治疗全体会议：中枢神经系统创作者：代红久、孙斌、杨东、徐晖、朱小金、魏佳、赵旭东内容可：2522广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后半期错配修复缺陷病症中的系统设计全体会议：开发中的放射治疗学-免疫放射治疗创作者：沈琳名誉教授等内容可：3021广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART放射治疗住院/难治性ACUTE淋巴本站粒体白血病/淋巴刺毛的首例人体临床检验全体会议: 开发性放射治疗学-免疫放射治疗创作者简介：张明志，杨林等内容可：3026广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 萨里替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）合组引入后半期单独刺毛病症的Ib期研究课题全体会议：发展性放射治疗学----分子可载体药物和免疫学创作者：龚继芳，沈琳名誉教授等内容可：3523广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin合组嘌呤和nedaplatin放射治疗住院性或转回性腹腔表皮本站粒体乳癌（ESCC）病症的II期研究课题。全体会议：小肠乳癌-胃腹腔、胰腺和脾胆道乳癌的研究课题创作者：王之志不强，李玉红，王之德申，王之凤华，任超，谭琼 王之志不强、李玉红、王之德深、王之凤华、任超、谭琼内容可：4522广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全体会议：小肠乳癌-胃腹腔乳癌、胰腺乳癌和脾肺乳癌的二本站放射治疗创作者：宋艳等内容可：4524广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿外体环状RNA本站性用作初始活检时扫描高等级乳癌的尿外体环状RNA本站性：一项多中心的回顾性研究课题全体会议：循环系统生殖系统乳癌症-----乳癌、脑乳癌和乳癌创作者简介：Liaoyuan Li等内容可：5522广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 发散后半期宫颈乳癌所发化学放射治疗后的常规化学放射治疗全体会议: 小儿乳癌症创作者简介： 李珉珉等内容可：6031广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼放射治疗睾丸髓性乳癌的相关性：基于ALTER01031检验的分析方法。会话：头颈部创作者：天津疗养院高明名誉教授内容可：6526广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和平均年龄对安洛替尼放射治疗后病症结局的受到影响: ALTER01031的亚组分析方法全体会议：头颈部创作者：天津疗养院高明名誉教授内容可：6527广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析方法预测I-IIIA期非小本站粒体白血病（NSCLC）病症术后住院: GASTO1035和GASTO1018的结果全体会议：白血病-非小本站粒体发散-区域性/小本站粒体/小本站粒体/其他胸科乳癌症创作者：Si-Yu Wang等内容可：9023广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小本站粒体白血病（NSCLC）中EGFR酪氨酸激酶胺的新的型致病机制全体会议:白血病-非小本站粒体转回性白血病创作者简介：赵昕，金小妹，满宇，欧秋香，华宝，薛武，杨少，范敏 赵昕、金小妹、满宇、欧秋香、华宝、薛武、杨绍、范敏内容可：9528广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1检验中后半期黑色素刺毛总生存的替代终点站全体会议：黑色素刺毛/皮肤乳癌创作者：聂润聪，袁书不强，李元芳，陈英波，周志伟 聂润聪、袁书不强、李元芳、陈英波、周志伟内容可：10030广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼放射治疗住院或转回性原发性恶性骨病症的II期研究课题全体会议： 恶性肿刺毛创作者：唐丽娜，牛晓辉，陈赓，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王之振、蔡启庆、涂崇奇、范正福、杨瑶内容可：11525广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 可行性评价安罗替尼在后半期恶性肿刺毛病症多本站放射治疗中的安全性和。全体会议：恶性肿刺毛创作者：姚伟涛，黄家不强，张瑞，王之林，杜新的辉，田志浩，牛晓颖 姚伟涛、黄家不强、张瑞、王之鑫、杜鑫辉、田志超、牛晓英内容可：11526广告：414